Analytical Data
-
Gene name
SPANXA1
- Application
-
Alternative Names
SPANXA1; SPANXA;; SPANXA2; Sperm protein associated with the nucleus on the X chromosome A; Cancer/testis antigen 11.1; CT11.1; Nuclear-associated protein SPAN-Xa; SPAN-X; SPANX-A; SPANX family member A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NS26
-
Expression Region
1-97 aa
-
AA Sequence
MDKQSSAGGV KRSVPCDSNE ANEMMPETPT GDSDPQPAPK KMKTSESSTI LVVRYRRNFK RTSPEELLND HARENRINPL QMEEEEFMEI MVEIPAK
-
Molecular Weight
11.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPANXA1 (spermatogenic and testis-specific protein) is a member of the cancer/testis (CT) antigen family, which is predominantly expressed in germ cells of the testis and in various malignant tumors, but not in normal somatic tissues. This unique expression pattern makes SPANXA1 an attractive target for immunotherapy, particularly in cancer treatment, as it can elicit immune responses while minimizing damage to normal cells. Research has indicated that SPANXA1 may play a critical role in tumorigenesis and potentially contribute to the survival and proliferation of cancer cells. Understanding the functional characteristics of SPANXA1 and developing recombinant SPANXA1 proteins can provide valuable insights into its biological role and enhance therapeutic strategies. The generation of SPANXA1 recombinant proteins allows for the examination of their antigenic properties and interactions with the immune system, paving the way for the development of targeted cancer vaccines. As a result, SPANXA1 is gaining attention in the fields of oncology and immunology, as researchers explore its potential implications in cancer diagnosis, prognosis, and treatment to improve patient outcomes.
